Termination of Development. At any time, and upon notice to CDCP, CVBT may elect to terminate the Development process due to insufficient progress or outright inability to make progress toward a commercially marketable wound healing drug.
Termination of Development. In the event either Party or its sublicensees determine at its or their sole discretion that further development of the Product by such Party or its sublicensees is commercially, financially, or otherwise not advisable or reasonable due to the reasons of (i) efficacy, (ii) safety, (iii) infringement of the Third Party’s patent or other intellectual property, or (iv) marketability or profitability, such Party and its sublicensees may terminate the development of the Product hereunder. In the event such Party (and its sublicensees, if any) have determined to terminate any and all of the development in certain country(ies) in such Party’s Territory, (a) such Party shall promptly give to the other Party written notice to that effect stating the date of termination of such development, (b) the license granted to such Party (including the sublicenses granted to such sublicensees) pursuant to Section 2.1(a) or 2.2(a), as applicable, shall terminate on such date with respect to such country(ies), (c) the other Party and its sublicensees shall have access to and the right to use all documents, data, results and other Information generated from or obtained by the development in such country(ies) hereunder by such Party or its sublicensees and (d) such Party shall, and shall cause its sublicensees to, cooperate with the other Party and its sublicensees for such access and right to use.
Termination of Development. At any time, and upon notice to CNG, CVBT may elect to terminate the Development process due to insufficient progress, overwhelming competition or outright inability to make progress toward a commercially marketable Heart drug.
Termination of Development. The Company hereby grants to the NIAID a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any invention which the Company may have or obtain on Test Article, its manufacture, or on the process for use of Test Article, throughout the world, for medical research purposes related to [Insert disease or disorder]. This license will only become effective in the event the Company terminates its development of Test Article for reasons other than safety, without the transfer of its development efforts to another party within ninety (90) calendar days of termination, and the NIAID elects to continue the development of Test Article. This provision will become null and void upon FDA approval of the Test Article indications and marketing of the Test Article by the Company.
Termination of Development. The Company hereby grants to the NIAID a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any invention which the Company has a right to license which the Company may have or obtain on Test Article, its manufacture, or on the process for use of Test Article, throughout the world, solely for medical research purposes related to Chronic Granulomatous Disease. This license will only become effective in the event the Company terminates its development of Test Article for reasons other than safety or IRB approval withdrawal, without the transfer of its development efforts to another party within […***…] of termination, and the NIAID elects to continue the development of Test Article. This provision will become null and void upon FDA approval of the Test Article indications and marketing of the Test Article by the Company.
Termination of Development. The Company hereby grants to the NIAID a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any invention which the Company may have or obtain on Test Article, its manufacture, or on the process for use of Test Article, throughout the world, for medical research purposes related to Engraftment and Immune Reconstitution in Patients with SCID. This license will only become effective in the event the Company terminates its development of Test Article for reasons other than safety, without the transfer of its development efforts to another party within […***…] of termination, and the NIAID elects to continue the development of Test Article. This provision will become null and void upon FDA approval of the Test Article indications and marketing of the Test Article by the Company. NIAID Intramural Clinical Trial Agreement (Clinical Center)Jasper Therapeutics-Division of Intramural Research, NIAID NIAID Protocol # […***…]
Termination of Development. In the event neither Party desires to proceed with the continued development of a Compound or Product pursuant to Sections 4.4: (i) each Party shall at its own expense promptly return to the other Party all relevant records and materials in its possession or control containing Confidential Information of the other Party (provided that such Party may keep one copy of such Confidential Information of the other Party for archival purposes only); and (ii) the licenses granted under Sections 6.1 and 6.2, including any sublicenses thereunder, shall terminate with respect to such Compound and all Products which contain such Compound.
Termination of Development. Company hereby grants to NHLBI a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any invention which Company may have or obtain on Test Article, its manufacture, or on the process for use of Test Article, throughout the world, for medical research purposes related to the Protocol for the sole purpose of completing the Clinical Trial. This license will only become effective in the event Company terminates its development of Test Article for reasons other than safety or IRB approval withdrawal, without the transfer of its development efforts to another party within […***…] of termination, and NHLBI elects to continue the development of Test Article. This provision will become null and void upon FDA approval of the Test Article indications and marketing of the Test Article by Company. Intramural Clinical Trial Agreement Page 11 of 22 Document Printed February 4, 0000 Xxxxxx Xxxxxxxxxxxx‒XXXXX XXX […***…]
Termination of Development. (a) Ligand acknowledges that the development and commercialization of Drug Products is an inherently uncertain process, and that there can be no assurance either that the Drug Products can be successfully developed or that the potential commercial rewards available from the commercialization of the Drug Products, when weighed against the costs and uncertainties involved and compared to Lilly's other commercial opportunities, will be sufficient to justify Lilly's continued efforts to discover, develop and/or commercialize the Drug Products. Lilly will devote the same degree of skill and effort to development of Drug Products as it devotes to its own products of similar risk and potential. If Lilly in good faith determines that further efforts under this Agreement, with respect to a particular Research Compound or Drug Product that has begun development, would not be in the best interests of Lillx, Xxxxx xxx cease development of such Research Compound or Drug Product. Lilly shall promptly notify Ligand of any election to discontinue development of a Development Candidate or Drug Product hereunder.
Termination of Development. P&U shall have the right at any time to terminate the development of a Candidate Drug upon notice to Geron. Upon such termination and subject to Section 4.4 herein, all rights to any such Candidate Drug which is a Geron Compound or a KH Compound shall revert to Geron. In the event such termination is attributable to safety or efficacy reasons with such Candidate Drug, P&U shall have one hundred eighty (180) days from the date of the termination notice (the "Replacement Period") in which to select a replacement Candidate Drug in accordance with Section 2.6(b). Geron shall not, directly or indirectly, [*] (or any such Compounds reverting to Geron pursuant to Section 5.3) for so long as P&U is actively developing a Candidate Drug in accordance with Article 3 above or actively commercializing a Product containing a Candidate Drug with royalties due to Geron in accordance with Article 7 and any Replacement Period, if applicable, has not lapsed.
